Forma Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2008)
Status: Acquired by Novo Nordisk (2022)

Organization Overview

First Clinical Trial
2015
NCT02543879
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Forma Therapeutics | Forma Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 3)

Cholangiocarcinoma (Phase 2)

Chondrosarcoma (Phase 2)

Fatty Liver (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overweight (Phase 2)

Preleukemia (Phase 2)

Prostatic Neoplasms (Phase 1)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 12